Standard Material Transfer Agreements 2 (SMTA2)
The SMTA2 is one of the two PIP Benefit Sharing mechanisms. It is a legally-binding contract between WHO and an influenza product manufacturer, research institution, or other entity that receives PIP Biological Materials, such as influenza viruses with pandemic potential (IVPP), from a laboratory which is part of the Global Influenza Surveillance and Response System (GISRS).
In exchange for access to PIP Biological Materials, the entity commits to provide to WHO benefits resulting from their use. This includes specific items that can be used to prepare for (e.g. training, technology license) or respond to (e.g. vaccines, antivirals, diagnostic kits) pandemic influenza.
By concluding SMTA2s now, these legally binding advance supply contracts ensure WHO will have predictable access to pandemic vaccine and other products.
Who is required to sign an SMTA2?
How are recipients of PIP biological materials traced and notified?
The purpose of the SMTA2 is to obtain legally binding commitments from users of PIP biological materials (including IVPP) to share certain benefits with WHO. Recognizing that there are different types of recipients PIP biological materials, the signatories are classified into the following three different categories:
- Category A: Influenza vaccine and antiviral manufacturers
- Category B: Manufacturers of other pandemic related products (e.g. diagnostic kits)
- Category C: All other recipients (universities, research institutions, bio-tech companies, etc.)
The recipients, depending on their nature and capacity, choose from the specific list of benefit options found in Annex 2, Article 4 of the PIP Framework and summarized in the table below.
Summary of the options available to each category of recipient of PIP Biological Materials: